Search

Your search keyword '"Cazzagon N."' showing total 338 results

Search Constraints

Start Over You searched for: Author "Cazzagon N." Remove constraint Author: "Cazzagon N."
338 results on '"Cazzagon N."'

Search Results

2. Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis

3. Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?

4. OC.05.7: CHOLESTASIS IMPACTS ON PERFORMANCE OF NON INVASIVE TESTS FOR RULING OUT HIGH-RISK ESOPHAGEALVARICES IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AND COMPENSATED ADVANCED CHRONIC LIVER DISEASE

5. Prevalence and significance of antimitochondrial antibodies in autoimmune hepatitis (AIH): Results from a large multicentre study of the International AIH Group

6. Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one-year non-responders and predicts survival

7. Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe

8. Patient-reported quality of care in primary sclerosing cholangitis

9. Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis

10. Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid

11. Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls

12. Primary biliary cholangitis: perception and expectation of illness

13. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055))

14. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group

15. Clinical update on risks and efficacy of anti-SARS-CoV-2 vaccines in patients with autoimmune hepatitis and summary of reports on post-vaccination liver injury

17. Long-term results from the Italian real-world experience on obeticholic acid treatment in primary biliary cholangitis: The RECAPITULATE study

18. People with autoimmune hepatitis and celiac disease have a milder liver disease course and a better chance of immunosuppressive treatment withdrawal.

21. Prediction of response to obeticholic acid in primary biliary cholangitis: Development and validation of the OCA response score (ORS)

23. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055))

24. Autoimmune biliary diseases: Primary biliary cholangitis and primary sclerosing cholangitis

25. Real-world experience with obeticholic acid in patients with primary biliary cholangitis

26. Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool

27. A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis

28. X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

29. Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis

30. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

31. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis

32. Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis

33. Accuracy of Liver Stiffness Measurement in assessing liver fibrosis in naïve patients with Primary Biliary Cholangitis

34. Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis

35. Machine learning in primary biliary cholangitis: A novel approach for risk stratification

36. T.08.3 CHARACTERISTICS AND SURVIVAL OF PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AND HEPATOCELLULAR CARCINOMA

37. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group

39. Predictors of Serious Adverse Event and Non-response in Cirrhotic Patients With Primary Biliary Cholangitis under Obeticholic Acid

42. Digestive diseases. 2022-2025 edition

44. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

45. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

46. X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

47. Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naïve patients with Primary Biliary Cholangitis: a dual cut-off approach

48. Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis

49. Cluster analysis reveals the prognostic role of serum albumin within the normal range in patients with primary biliary cholangitis

50. Clustering Reveals the Prognostic Role of Serum Albumin Values Within the Normal Range in Patients with Primary Biliary Cholangitis

Catalog

Books, media, physical & digital resources